Int'l : +1-503-894-6022 | Toll Free : +1-800-792-5285 | help@alliedmarketresearch.com
A11140 | Pages: NA | Charts: NA | Tables: NA |
Hypertrophic cardiomyopathy (HCM) is a disorder where the heart muscle becomes abnormally thick or hypertrophied. The thickened heart muscle causes the heart to be inefficient in pumping blood and was a heavier load for it to do so. This disease often goes undiagnosed because many people with the disease have no or lesser symptoms. However, sometimes people with HCM, the thickened heart muscle may lead to shortness of breath, chest pain or problems in the heart's electrical system, resulting in life-threatening abnormal heart rhythms (arrhythmias) or sudden death. The therapies include beta-blockade and verapamil alone or in combination, though verapamil may provoke LVOTO-associated symptoms in some individuals due to its vasodilatory effect. Disopyramide may be given to the patients with symptoms refractory to the use of beta-blocker or even the calcium channel blocker therapy.
COVID-19 scenario analysis:
Coronavirus disease 2019 (COVID-19) has led to a situation of lockout, and has led to economic crisis along with health care crisis. The pandemic has led to downturn of healthcare system in developed countries and are predictable to cause economic recession. It has an adverse impact on the healthcare system, which is leading to the reduction in the growth of the industry and caused loss of 50% to 70% drop in revenue from March. Many small hospitals, clinics and nursing homes, have been asked to close their operations. As a result of the increase in the deaths of the health professionals due to the exposure to the infected patients, a reduction in the number assisting in the management of the disease is being observed and hence may hinder the growth of the industry. The surgical procedures are also reduced due to the susceptibility of the infection to affect the normal individual, hence causing a global economic recession in the current scenario.
The major factors affecting the market include, the rise in the number of population experiencing heart diseases, which is among the major causes of death globally, which would help the market flourish. The growth in awareness programs carried out by various organizations regarding the lethality of the disease would boost the industry of Hypertrophic Cardiomyopathy Therapeutics in the forecast period. The growth in the R&D of the drugs used for the treatment is anticipated to help the industry grow. The product launches henceforth are expected to help the market boost in the coming years. However, the stringent regulations may hinder the market growth in the next few years.
In May 2020, MyoKardia, Inc. announced positive topline data from the company’s Phase 3 pivotal EXPLORER-HCM clinical trial of mavacamten for the treatment of patients with symptomatic, obstructive hypertrophic cardiomyopathy (HCM). Mavacamten demonstrated a robust treatment effect, the primary and all secondary endpoints of the EXPLORER trial were met with statistical significance (p≤0.0006 for all endpoints).
In July 2019, Cytokinetics, Incorporated had announced that preclinical data for CK-3773274 (CK-274) were presented at the American Heart Association’s Basic Cardiovascular Sciences (BCVS) Scientific Sessions in Boston, showing that CK-274 decreased cardiac contractility in vitro, in vivo in healthy animals, and in vivo in a mouse model of hypertrophic cardiomyopathy (HCM). CK-274 is a novel cardiac myosin inhibitor, discovered by company scientists, in development for the potential treatment of HCM which may result from increased cardiac contractility.
The key market players are focusing on getting into collaborations in order to expand their product folio and gain the attention of the market and hence gain the maximum shares and is anticipated to help the market propel in the forecast period. For instance, AstraZeneca which is a global science-led biopharmaceutical company that focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in three therapy areas such as Oncology, Cardiovascular, Renal & Metabolism and Respiratory.
In March 2019, AstraZeneca had entered into a global development and commercialization collaboration agreement with Daiichi Sankyo Company, Limited (Daiichi Sankyo) for trastuzumab deruxtecan (DS-8201), a proprietary antibody-drug conjugate (ADC) and potential new targeted medicine for cancer treatment. The collaboration is aligned with AstraZeneca’s science-led strategy in Oncology, which is based on four key scientific platforms: tumor drivers & resistance, DNA damage response, Immuno-Oncology and ADCs.
Key benefits of the report:
Questions answered in the Hypertrophic Cardiomyopathy Therapeutics Market research report:
Key Market Segments
Key Market Players
Other Players